MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Other Non-current Assets
Long-term assets not reported separately.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Other Non-current Assets · Q3 FY2026 · quarter ended Sep 2026
Other non-current assets rises 394.0% from a year ago
Other non-current assets stood at $247K at the end of Q3 FY2026, up 394.0% from a year earlier and down 60.5% from the prior quarter. Over 3 fiscal years it compounded at +108.9% a year.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +394.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 383K USD
- Year-over-year change
- +666.0%
- 3-year CAGR
- +108.9%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 383K | +666.0% |
| FY2024 | 2024-12-31 | 50K | +0.0% |
| FY2023 | 2023-12-31 | 50K | +19.0% |
| FY2022 | 2022-12-31 | 42K | — |
Other Non-current Assets vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +394.0% is the 3rd highest of 8, against a peer median of +12.9%.
- Other non-current assets amounts to 0.0% of total assets for MBX, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $270.6M USD | — | — | 22.3% |
| Sep 2026 | €25.64M EUR | +711.4% | — | 1.1% | |
| Sep 2026 | $3.83M USD | +21.8% | -39.2% | 0.9% | |
| Mar 2026 | $1.1M USD | +12.9% | +3.3% | 0.3% | |
| Mar 2026 | $746K USD | -53.9% | +32.3% | 0.2% | |
| Jun 2026 | $324K USD | +500.0% | -13.5% | 0.1% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $247K USD | +394.0% | +108.9% | 0.0% |
| Mar 2026 | $48K USD | -98.9% | +371.8% | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding MBX) | — | +12.9% | +3.3% | 0.3% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.